NeuroProtect – A novel therapy to prevent Chemotherapy-Induced Peripheral Neuropathy
The NeuroProtect project aims to prevent chemotherapy-induced peripheral neuropathy by using Localised Microvascular Compression Therapy to reduce drug delivery to peripheral nerves during treatment.
Projectdetails
Introduction
Chemotherapy induced peripheral neuropathy (CIPN) is a debilitating neural condition that affects millions of European cancer patients every year. It is considered by patients and oncologists to be the most significant long-term impact of cancer treatment and often results in devastating consequences for patients, including an inability to work or perform the basic tasks of daily living.
Urgent Need
With chemotherapy usage set to increase by 53% by 2040, CIPN remains a clear and urgent unmet patient need. CIPN is the loss of sensation and movement in the hands and feet induced by chemotherapy treatment and is often associated with chronic neuropathic pain.
Mechanism of CIPN
Chemotherapy drugs enter the bloodstream and target all fast-growing, rapidly multiplying cells – a known characteristic of cancerous cells. However, many cells of this nature occur naturally in the body, including peripheral nerve cells. Thus, a well-known side effect of chemotherapy is the demyelination of these peripheral nerves (i.e., the destruction of the protective coating of nerve cells).
Localised Microvascular Compression Therapy (LMCT)
Localised Microvascular Compression Therapy (LMCT) is a concept developed by the PI focused on temporarily reducing blood flow and unwanted chemotherapy drug delivery at the peripheral nerve fibres during chemotherapy treatment.
Mechanism of Action
By applying a consistent low-level pressure (between 40 and 60 mmHg) across the skin surface of the hands and feet, the local micro-blood vessels (which deliver chemotherapy drugs to the nerve fibres) are temporarily occluded. This causes local chemotherapy delivery to be drastically reduced, thus preventing destruction of long-chain myelin and maintaining neural function.
Note: Short-term and controlled blood flow reductions have been shown to cause no tissue damage.
Conclusion
In this way, the NeuroProtect project will deliver a safe and pain-free solution to prevent CIPN during chemotherapy treatment.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-11-2023 |
Einddatum | 30-4-2025 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITY OF GALWAYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Overcoming Mechanically-Induced Resistance to Chemo-Immunotherapy in Pancreatic CancerThis project aims to identify and overcome mechanoresistance in pancreatic cancer using bioengineering methods to enhance chemotherapy efficacy and improve patient-specific treatment strategies. | ERC Advanced... | € 2.500.000 | 2025 | Details |
Live biotherapeutics to potentiate cancer immunotherapyThe project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models. | ERC Proof of... | € 150.000 | 2023 | Details |
Decrypting neuro-cancer crosstalk in pediatric cancers of the peripheral nervous systemThis project aims to explore the interactions between neurobiology and neuroblastoma to identify therapeutic targets and define subtypes benefiting from neuro-related treatments. | ERC Starting... | € 1.836.141 | 2024 | Details |
Targeted nanohorns for lithium neutron capture therapyTARLIT aims to enhance neutron capture therapy for cancer by using nanoparticles to deliver enriched lithium compounds, improving treatment precision and efficacy against tumors. | ERC Proof of... | € 150.000 | 2023 | Details |
Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapyThis project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling. | ERC Starting... | € 1.500.000 | 2023 | Details |
Overcoming Mechanically-Induced Resistance to Chemo-Immunotherapy in Pancreatic Cancer
This project aims to identify and overcome mechanoresistance in pancreatic cancer using bioengineering methods to enhance chemotherapy efficacy and improve patient-specific treatment strategies.
Live biotherapeutics to potentiate cancer immunotherapy
The project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models.
Decrypting neuro-cancer crosstalk in pediatric cancers of the peripheral nervous system
This project aims to explore the interactions between neurobiology and neuroblastoma to identify therapeutic targets and define subtypes benefiting from neuro-related treatments.
Targeted nanohorns for lithium neutron capture therapy
TARLIT aims to enhance neutron capture therapy for cancer by using nanoparticles to deliver enriched lithium compounds, improving treatment precision and efficacy against tumors.
Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapy
This project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair LossLILY is a portable device that prevents chemotherapy-induced hair loss by using localized microvasculature compression therapy to inhibit drug delivery to hair follicles. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Behandeling diabetische neuropathie m.b.v. EVNSNeurecon onderzoekt technische en financiële risico's van een veelbelovende behandeling voor diabetische neuropathie. | Mkb-innovati... | € 20.000 | 2022 | Details |
Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss
LILY is a portable device that prevents chemotherapy-induced hair loss by using localized microvasculature compression therapy to inhibit drug delivery to hair follicles.
Behandeling diabetische neuropathie m.b.v. EVNS
Neurecon onderzoekt technische en financiële risico's van een veelbelovende behandeling voor diabetische neuropathie.
Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1
The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments.
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.